Cytotherapy · 2024 · 10 citations · 54 references
Life SciencesImmunologyNeuroscienceDrug DeliveryInflammationNeuroimmunologyMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyMultiple SclerosisNanomedicineNeuroinflammationNeuroprotectionAdipose Stem CellsAdipose-derived Mesenchymal Stem CellsEx Vivo DeliveryExperimental Autoimmune EncephalomyelitisExtracellular VesiclesInflammatory Neurologic DisordersIron Oxide NanoparticlesMultiple Sclerosis Therapy
BACKGROUND AIMS: Adipose mesenchymal stem cells (ASCs) represent a promising therapeutic approach in inflammatory neurological disorders, including multiple sclerosis (MS). Recent lines of evidence indicate that most biological activities of ASCs are mediated by the delivery of soluble factors enclosed in extracellular vesicles (EVs). Indeed, we have previously demonstrated that small EVs derived from ASCs (ASC-EVs) ameliorate experimental autoimmune encephalomyelitis (EAE), a murine model of MS. The precise mechanisms and molecular/cellular target of EVs during EAE are still unknown. METHODS: To investigate the homing of ASC-EVs, we intravenously injected small EVs loaded with ultra-small superparamagnetic iron oxide nanoparticles (USPIO) at disease onset in EAE-induced C57Bl/6J mice. Histochemical analysis and transmission electron microscopy were carried out 48 h after EV treatment. Moreover, to assess the cellular target of EVs, flow cytometry on cells extracted ex vivo from EAE mouse lymph nodes was performed. RESULTS: Histochemical and ultrastructural analysis showed the presence of labeled EVs in lymph nodes but not in lungs and spinal cord of EAE injected mice. Moreover, we identified the cellular target of EVs in EAE lymph nodes by flow cytometry: ASC-EVs were preferentially located in macrophages, with a consistent amount also noted in dendritic cells and CD4+ T lymphocytes. CONCLUSIONS: This represents the first direct evidence of the privileged localization of ASC-EVs in draining lymph nodes of EAE after systemic injection. These data provide prominent information on the distribution, uptake and retention of ASC-EVs, which may help in the development of EV-based therapy in MS.
54
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy
Emanuela Zappia, Simona Casazza, Enrico Pedemonte et al. · Blood · 2005 · 1.4K citations · Full text
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Olle Ringdén, Mehmet Uzunel, Ida Rasmusson et al. · Transplantation · 2006 · 1.1K citations